Ketotifen structure
|
Common Name | Ketotifen | ||
---|---|---|---|---|
CAS Number | 34580-13-7 | Molecular Weight | 309.42500 | |
Density | 1.236g/cm3 | Boiling Point | 488.9ºC at 760mmHg | |
Molecular Formula | C19H19NOS | Melting Point | 152-153ºC | |
MSDS | N/A | Flash Point | 249.5ºC |
Use of KetotifenKetotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention[1][2][3][4]. |
Name | 10-(1-methylpiperidin-4-ylidene)-5H-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one |
---|---|
Synonym | More Synonyms |
Description | Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
Histamine 1, SARS-CoV-2, Influenza virus[1][3][4] |
In Vitro | Ketotifen (0-100 μM; 2 or 4 days) inhibits SARS-CoV-2 with an EC50 of 48.9 μM; and increases the percentage inhibition of SARS-CoV-2 to 79%, 83% and 93% when co-administers with 25, 50 and 100 μM Indomethacin, respectively[3]. Ketotifen (0-50 μM; 24 h) has inhibitory activity against PR8, pH1N1 and H3N2 with EC50s of 5.9 μM, 33.7 μM and 48.5 μM, respectively; and exhibits relatively low cytotoxicity in MDCK cells (EC50=291 μM)[4]. |
In Vivo | Ketotifen (80 mg/kg; i.g.; daily for 3 days) reduces end organ damage and mortality in mice infected with influenza virus[4]. Ketotifen (0.4 mg/kg; i.p.; daily for 10 days) reduces encephalomyelitis (EAE) prevalence and severity[5]. Animal Model: Female C57BL/6 mice (4-6 weeks; intranasal infection with 1×103 TCID50 of PR8 in 30 μL of DMEM)[4] Dosage: 80 mg/kg Administration: i.g.; daily for 3 days Result: Reduced end organ damage and mortality in infected mice. Animal Model: Female C57BL/6 mice (5-6 weeks old; subcutaneously immunized with 150 μg of MOG35-55 peptide containing 4 mg/mL of Mycobacterium tuberculosis)[5] Dosage: 0.4 mg/kg Administration: i.p.; daily for 10 days (from the 7th day of infection) Result: Reduced EAE prevalence and severity; reduced oxidative stress status and inflammasome activation at the CNS; reduced the amount of T cells, especially Th1, in the CNS; downregulated local mRNA expression for mast cell enzymes and preserves blood-CNS barrier permeability; triggered lymphocyte accumulation in draining lymph nodes. |
References |
Density | 1.236g/cm3 |
---|---|
Boiling Point | 488.9ºC at 760mmHg |
Melting Point | 152-153ºC |
Molecular Formula | C19H19NOS |
Molecular Weight | 309.42500 |
Flash Point | 249.5ºC |
Exact Mass | 309.11900 |
PSA | 48.55000 |
LogP | 3.95230 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xn |
---|
Precursor 9 | |
---|---|
DownStream 3 | |
Ketotifeno |
Ketotiphene |
Ketotifene |
Ketotiphen |
Ketotifenum |
ketotifen |
Zaditen |